Please login to the form below

Not currently logged in
Email:
Password:

CRISPR Therapeutics appoints Dr Tony Coles

He takes up a seat on the Swiss biopharma's board of directors

CRISPR Tony ColesSwiss biopharma company CRISPR Therapeutics has appointed Dr Tony Coles to its board of directors.

He is currently founding investor, chairman and chief executive officer of Yumanity Therapeutics, a biotechnology company focused neurodegenerative diseases.

Rodger Novak, chief executive officer of CRISPR Therapeutics, said: “Dr Coles is a venerated leader in the biotech industry with a strong track record of success.

“The appointment of Dr Coles is in line with our effort to bring the best talent to CRISPR Therapeutics and rapidly become a leading biopharmaceutical company devoted to discovering and developing novel medicines for patients suffering from diseases with limited treatment options.”

Prior to founding Yumanity Dr Coles served as chairman and chief executive officer of Onyx Pharmaceuticals, which was acquired by Amgen in 2013 for $10.5bn.

He has also previously held executive and leadership positions at NPS Pharmaceuticals, Vertex Pharmaceuticals, Bristol-Myers Squibb and Merck & Co.

6th January 2016

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
OUTiCO

Providing an exceptional outsourcing service to the Pharma & Healthcare industries. We offer a sustainable approach and drive sales outcomes...

Latest intelligence

OUTiCO win Best in UK Pharmaceutical Outsourcing award
The Corporate LiveWire Healthcare and Life Sciences Awards celebrate global companies and individuals who have excelled over the past 12 months....
artificial-intelligence-in-healthcare.jpg
Artificial Intelligence in Healthcare
Artificial intelligence is already out-diagnosing experts, but would you put a computer in charge of your healthcare? The good, the bad; we take a look....
World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer
Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...

Infographics